*Patient verbatim and profile comes from hypothetical patient for illustrative purpose only
†Data from ASTERIA II; two other phase III studies (ASTERIA I and GLACIAL) were also conducted to assess efficacy and safety of Xolair® in inadequately controlled CSU patients
‡Xolair® 300mg vs. baseline at 12 weeks; p<0.001 vs placebo. DLQI Dermatology Life Quality Index
References: 1. Zuberbier T, et al. Allergy 2014; 69:868-887. 2. Maurer M, et al. Allergy 2011; 66:317-330. 3. Greaves M. Allergy Clin Immunology 2000; 105:664-672. 4. Maurer M, et al. N Engl J Med 2013; 368:924-935.